anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Blood processing systems and methods are disclosed. A processing chamber (14) rotating on a rotating element includes a first compartment (38) and a second compartment (40). Blood is conveyed into the first compartment (38) for centrifugal separation into components. A liquid free of blood occupies the second compartment (40) to counter-balance the first compartment (38) during rotation on the rotating element. In one embodiment, the second compartment (40) is served by a single fluid access. Prior to use, the single access is coupled to tubing, through which a vacuum is drawn to remove air from the second compartment (40). While vacuum exists, communication is opened between the tubing and a source of liquid. The vacuum draws the liquid into the second compartment (40) through the single access, thereby priming the second compartment (40) for use.
Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
PURPOSE: A hair styling composition containing a fiber and a powder dispersing agent is provided to improve physical properties of a setting agent and oil and fat components and to maintain hair style. CONSTITUTION: A hair styling composition contains a fiber and a powder dispersing agent. The fiber includes nylon, polyester, rayon, silk, cotton, or wool. The powder dispersing agent is polyoxyethyelne glyceryltriisostearate. The composition further contains high melting point oil and fat components such as carnauba wax, candellila wax, bee's wax, microcrystalline wax, paraffin wax, polyethylene, shellac wax or sunflower wax. The composition also contains a setting agent such as polyvinyl pyrrolidone, polyvinyl pyrrolidone/vinyl acetate copolymer, vinyl pyrrolidone/methacrylamide/vinylimidazole copolymer, polyvinyl alcohol, polyethylene glycol, polyquaternium, methacryloylethyl betaine/methacrylate copolymer, acrylate/octyl acrylamide copolymer, acrylate/t-butylacrylamide copolymer, or octylacrylamide/acrylate/butyladminoethyl metharcrylate. The composition contains water or ethanol.
CMR was performed in 38 consecutive patients with AMI 3±1 days after successful reperfusion using a clinical 1.5 Tesla MR-scanner. Ten healthy volunteers served as controls. SENC is a technique that directly measures peak circumferential strain from long-axis views and peak longitudinal strain from short axis views. Measurements were obtained for each segment in a modified 17 segment model. Wall motion and infarcted tissue were evaluated semi-quantitatively from SSFP cine sequences and contrast-enhanced-MR-images and were then related to myocardial strain. Comparison of peak circumferential strain assessed by SENC and MR-tagging was performed.
Provided are systems, methods and devices for adaptive and exception-based asset tracking by geolocation, while preserving battery life, ensuring patient privacy and maintaining interoperability by preventing interference with the operation of tracked medical devices. To prevent RF interference with medical device operation, provided are methods of detecting medical device operation through detection of magnetic fields or vibrations. For patient privacy, geolocation information received from an asset tracker device is anonymized and not stored. The asset tracker device described herein may be further configured to track elevation of an asset above the ground, movement of the asset, pressure and temperature changes to the environment and accordingly modify tracking behavior. Also provided is a pairing system for physical and electronic pairing of an asset tracker device to multiple medical devices. The asset tracked is mated with a cradle that is specific to the medical device type and attached to the medical device.
The present invention is a method for using thiazin dyes, especially methylene blue, in combination with light to hydroxylate guanosine or deoxyguanosine at the C8 of the purine ring. The number of guanosines in a nucleic acid strand converted to 8-OH-deoxyguanosine (8-OH-dG) or 8-OH-guanosine (8-OH-G) can be controlled through manipulation of the concentration of methylene blue, light intensity and length of exposure, pH, and buffer strength. The method can be used for the selective mutation or modification of either a DNA or a RNA sequence, or the protein expressed therefrom. The method can also be used in the treatment of viral infectons and in cancer. Methylene blue is FDA approved for topical, i.v., and oral administration. Viruses, bacteria, and cells undergoing rapid DNA synthesis are all inactivated by methylene blue in the presence of light or when irradiated.
Acute upper gastrointestinal bleeding (UGIB) is a common medical emergency which has a variceal and non-variceal etiology. The non variceal etiology has higher incidence in many countries. In Egypt, non-variceal causes ranged from 26.1% to 61.6% among UGIB cases presented to the emergency departments of different University Hospitals. Guidelines recommend risk stratification early in the management of patients with acute UGIB to help triage patients into the appropriate level of care. Many scoring systems for UGIB were developed and validated from 1990s onwards. Their primary aim was to segregate the patients into low-risk and high-risk groups. High risk patients with UGIB includes those who reach some or all of the endpoints: requirement of blood transfusion, endo-therapeutic, surgical or radiological intervention to achieve hemostasis, re bleeding and mortality. Unfortunately, no single risk score has been shown to be accurate at measuring all relevant outcomes.

The most widely used score is Glasgow Blatchford "GBS" which is a pre endoscopic score. It is useful in prediction of therapeutic intervention for bleeding. More recently, other scores have been developed as ABC score which showed good performance for predicting mortality. MAP score highly predicted therapeutic intervention and mortality. H3B2 score predicted the need of urgent hemostasis.

Limited data are available on the validity of the new scoring systems in predicting the outcome of Egyptian non-cirrhotic patients with acute UGIB. Therefore, The investigators will conduct our study to shed some light on this topic.
INTRODUCTION: Acute compartment syndrome of the thigh after total knee arthroplasty is a rarely described complication. After the assessment of the diagnosis, immediate surgical intervention is necessary to prevent further tissue damage. Since only a few cases have been described and because of the high complication rate, early detection is essential for ensuring patient outcomes.
CASE PRESENTATION: After total knee arthroplasty in a high-volume university hospital, a 57-year-old Caucasian female patient experienced strong, disproportional pain in the ventromedial thigh of the affected leg, which did not respond to an adequate adjustment in pain medication. Imaging revealed a distinct swelling of the vastus intermedius muscle. This resulted in acute compartment syndrome of the thigh, which was immediately surgically treated. Apart from receiving surgery distal from the affected compartment and continuous intake of acetylsalicylic acid, the patient had no risk factors for developing compartment syndrome. The patient's recovery was uneventful, with timely wound closure and discharge to outpatient care without significant functional limitations.
CONCLUSION: Acute compartment syndrome of the thigh represents a rare, but severe complication that can occur after orthopedic surgery. In our case, no triggering factors for the development of acute compartment syndrome, such as the use of a tourniquet, were detected. Even in unusual locations, compartment syndrome should be considered as a differential diagnosis. With sufficient evidence, immediate fasciotomy should be indicated.
The enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3) is a critical regulator of glycolysis and plays a key role in modulating the inflammatory response, thereby contributing to the development of inflammatory diseases such as sepsis. Despite its importance, the development of strategies to target PFKFB3 in the context of sepsis remains challenging. In this study, we employed a miRNA-based approach to decrease PFKFB3 expression. Through multiple meta-analyses, we observed a downregulation of miR-106a-5p expression and an upregulation of PFKFB3 expression in clinical sepsis samples. These changes were also confirmed in blood monocytes from patients with early sepsis and from a mouse model of lipopolysaccharide (LPS)-induced sepsis. Overexpression of miR-106a-5p significantly decreased the LPS-induced increase in glycolytic capacity, inflammatory response, and pyroptosis in macrophages. Mechanistically, we identified PFKFB3 as a direct target protein of miR-106a-5p and demonstrated its essential role in LPS-induced pyroptosis and inflammatory response in macrophages. Furthermore, treatment with agomir-miR-106a-5p conferred a protective effect in an LPS mouse model of sepsis, but this effect was attenuated in myeloid-specific Pfkfb3 KO mice. These findings indicate that miR-106a-5p inhibits macrophage pyroptosis and inflammatory response in sepsis by regulating PFKFB3-mediated glucose metabolism, representing a potential therapeutic option for the treatment of sepsis.
Patients receive oleclumab IV over 1 hour every 2 weeks for 5 doses, then every 4 weeks thereafter. Patients also receive durvalumab IV over 1 hour every 4 weeks. Cycle repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Indole-3-acetic acid (IAA) is the most widely utilized plant growth regulator. Despite its extensive usage, IAA is often overlooked as an environmental pollutant. Due to its protein-binding nature, it also functions as a uremic toxin, contributing to its association with chronic kidney disease (CKD). While in vitro and epidemiological research have demonstrated this association, the precise impact of IAA on cardiovascular disease in animal models is unknown. The main objective of this study is to conduct a mechanistic analysis of the cardiotoxic effects caused by IAA using male Wistar albino rats as the experimental model. Three different concentrations of IAA (125, 250, 500 mg/kg) were administered for 28 days. The circulating IAA concentration mimicked previously observed levels in CKD patients. The administration of IAA led to a notable augmentation in heart size and heart-to-body weight ratio, indicating cardiac hypertrophy. Echocardiographic assessments supported these observations, revealing myocardial thickening. Biochemical and gene expression analyses further corroborated the cardiotoxic effects of IAA. Dyslipidemia, increased serum c-Troponin-I levels, decreased SOD and CAT levels, and elevated lipid peroxidation in cardiac tissue were identified. Moreover, increased expression of cardiac inflammatory biomarkers, including ANP, BNP, β-MHC, Col-III, TNF-α, and NF-κB, was also found in the IAA-treated animals. Histopathological analysis confirmed the cardiotoxic nature of IAA, providing additional evidence of its adverse effects on cardiovascular health. These results offer insights into the potential negative impact of IAA on cardiovascular function, and elucidating the underlying mechanisms of its cardiotoxicity.
Chronic pain populations exhibit greater prevalence of benzodiazepine (BZD) prescription (vs. the general population) and greater likelihood of BZD use not as prescribed and dependence symptoms. Individuals report taking BZDs for pain relief, potentially contributing to maintenance/escalation of BZD use and hazardous couse with prescription opioids. Identifying cognitive factors underlying pain-BZD use relations represents a critical step toward understanding the role of pain in BZD use trajectories. Outcome expectancies for substance-related analgesia have been implicated in pain-substance use comorbidity (e.g., alcohol), and there is reason to believe these processes may extend to BZD use. The present study aimed to examine psychometric properties of a newly adapted Expectancies for Benzodiazepine Analgesia (EBA) scale and probe associations between EBA scores and prescription opioid use behaviors. Participants were 306 adults (38.9% females) endorsing chronic pain and current BZD prescription who completed an online survey. Results provided initial support for psychometric validity of the EBA: evidence of single-factor structure with good model fit (Bollen-Stine bootstrap p = .101), excellent internal consistency (α = .93), and evidence of concurrent validity via correlations with pain variables, likelihood of BZD use not as prescribed, BZD dependence symptoms, and self-reported BZD use for pain relief. Exploratory findings among participants prescribed opioids indicated positive covariation between EBA scores and behaviors associated with higher risk opioid use. This is, to our knowledge, the first study to assess analgesia expectancies for BZD use. BZD analgesic expectancies warrant further study as a treatment target in comorbid pain and BZD use. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
I. 1. Urine is in the blood and poison can not be discharged, so that the urine is discharged from the intestine via the vehicles of intestinal tract. II. 1. Urine is in blood. A. Activating the parental anabolism B. Belonging to the transamination of intestine-blood circulation C. Converting N.U into N+U D. Separating uremic toxins from blood 2. Urine is discharged from intestine A. Activating intestinal catabolism B. Belonging to the deamination of Krebs cycle C. Converting N+U into N.U D. Discharging uremic toxins from large intestine.
PURPOSE:To obtain a stable immunogen composition for oral administration by making a dried sphere comprising an immunogen capable of immunizing human body or animal and a specific gelatin enteric. CONSTITUTION:A composition which comprises a dried sphere comprising an immunogen (e.g. immunogen for influenza, Japanese B encephalitis, hepatitis B, pertussis or non-A, non-B type hepatitis) capable of immunizing human body or animal and a gelatin having 80,000-120,000 average-molecular weight and >=150 (bloom, g.6.2/3%) jelly strength and is made enteric by coating with an enteric coat and enteric capsulation. The amount of the immunogen used is preferably 1/50-1/10<8> (weight ratio) to gelatin. Gelatin is uniformly mixed with a buffering sodium chloride injection containing an immunogen at low temperature and heated to give a gel, which is poured into a liquid which is non- compatible with water and is physiologically atoxic to form soft spheres. The soft spheres are dried at low temperature to give solid spheres, which are made enteric to give the objective immunogen composition.
Theiler's murine encephalomyelitis virus (TMEV) infection has been used as a mouse model for two virus-induced organ-specific immune-mediated diseases. TMEV-induced demyelinating disease (TMEV-IDD) in the central nervous system (CNS) is a chronic inflammatory disease with viral persistence and an animal model of multiple sclerosis (MS) in humans. TMEV infection can also cause acute myocarditis with viral replication and immune cell infiltration in the heart, leading to cardiac fibrosis. Since platelets have been reported to modulate immune responses, we aimed to determine the role of platelets in TMEV infection. In transcriptome analyses of platelets, distinct sets of immune-related genes, including major histocompatibility complex (MHC) class I, were up- or downregulated in TMEV-infected mice at different time points. We depleted platelets from TMEV-infected mice by injecting them with platelet-specific antibodies. The platelet-depleted mice had significantly fewer viral antigen-positive cells in the CNS. Platelet depletion reduced the severities of TMEV-IDD and myocarditis, although the pathology scores did not reach statistical significance. Immunologically, the platelet-depleted mice had an increase in interferon (IFN)-γ production with a higher anti-TMEV IgG2a/IgG1 ratio. Thus, platelets may play roles in TMEV infection, such as gene expression, viral clearance, and anti-viral antibody isotype responses.
5 Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure. The microwells contain one or more active agents, alone or in combination, in one or more dosages 10 and/or release pharmacokinetics. In an exemplary embodiment, the device has a cylindrical shape, having symmetrical wells on the outside of the device, each well containing one or more drugs, at one or more concentrations, sized to permit placement using a catheter, cannula, or stylet. Optionally, the device has a guidewire, and fiber optics, sensors and/or interactive features such as 15 remote accessibility (such as WiFi) to provide for in situ retrieval of information and modification of device release properties. In the most preferred embodiment, the fiber optics and/or sensors are individually accessible to discrete wells. 3510886_1.docx
The present invention relates to fragrance precursors. In particular, the invention relates to the use of various classes of compounds which can act as fragrance precursors, for example, in cosmetic products such as deodorants and anti-perspirants, and in laundry products such as detergents and fabric softners. These compounds are normally odorless or almost odorless when coming into contact with the skin, for example, in compositions for skin care or compositions for personal care produce fragrances. The compounds also produce fragrances when used in the presence of lipases, for example, such as those used in detergents (laundry), thus providing a prolonged perfumed effect of the fabrics. The compounds under consideration are the compounds of formula I: (See formula). The substituents are defined in the specification.
Throughout the last two centuries, vaccines have been helpful in mitigating numerous epidemic diseases. However, vaccine hesitancy has been identified as a substantial obstacle in healthcare management. We examined the epidemiological dynamics of an emerging infection under vaccination using an SVEIR model with differential morbidity. We mathematically analyzed the model, derived R0, and provided a complete analysis of the bifurcation at R0=1. Sensitivity analysis and numerical simulations were used to quantify the tradeoffs between vaccine efficacy and vaccine hesitancy on reducing the disease burden. Our results indicated that if the percentage of the population hesitant about taking the vaccine is 10%, then a vaccine with 94% efficacy is required to reduce the peak of infections by 40%. If 60% of the population is reluctant about being vaccinated, then even a perfect vaccine will not be able to reduce the peak of infections by 40%.
PURPOSE: To obtain the powdery processed food of Momorodica charantia L., capable of being processed without deteriorating the active ingredients of the Momorodica charantia L., capable of being stored for a long period, free from a bitter taste, and capable of being utilized as a food material for various foods. CONSTITUTION: A Momorodica charantia L. is washed to remove the seeds and the endocarps contained therein, cut into fine pieces, dehydrated, and then dried in the sun or forcibly into a weight of 12-5wt.% based on the original whole weight of the fine cut pieces. The dried fine pieces are roasted at 60-120 deg.C and then pulverized. Thus, the powdery processed food of the Momorodica charantia L. free from a bitter taste and having a mild taste and a fragrant smell is obtained. When the dried fine pieces are pulverized without being roasted, the green powdery processed food of the Momorodica charantia L. is obtained. These foods can be dissolved in hot water or cold water to utilize as beverages, or can be mixed with other food materials to utilize as food flours, confection materials, etc.
In clinical studies, other local anesthetics (including ropivacaine and lidocaine) have been administered before, during, or after application of ZYNRELEF without evidence of local anesthetic systemic toxicity. Administration of ZYNRELEF with other formulations of local anesthetics, including bupivacaine liposome injectable suspension, has not been studied [see Warnings and Precautions (5.3)].

The toxic effects of local anesthetics are additive. Avoid additional use of local anesthetics within 96 hours following administration of ZYNRELEF. If co-administration cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1), Warnings and Precautions (5.1) and Overdosage (10)].

Patients who are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics (Table 5).
Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
PURPOSE: The survival rate (SR) for neonates born with congenital diaphragmatic hernia (CDH) remains high. Our aim was to investigate the change in SR in children with CDH over the past decades.
METHODS: The study was a nationwide, population-based prospective nested case-control study within a cohort of newborn children who was born in Sweden during the observational period from 1st January 1982 to 31st December 2015.
RESULTS: In the study period, 4654 (99.6%) control children and 684 children with CDH (70.4%, p < 0.001) were with a survival of 2 years of age. Any patients who were born with CDH had a overall 5.8 times higher chance for not surviving 2 years of age than children without CDH. The SR improved significantly in CDH in the past 3 decades. Significantly higher number of patients were prematurely born in the CDH group than in the controls (23.3 vs 6.1%, p < 0.001). The SR of premature and non-premature born CDH patients has increased significantly over the past 3 decades.
CONCLUSION: The SR of CDH patients were significantly increased in the past 3 decades. The 2-year survival remains 5.8 times higher than those who were not born with CDH. These changes were mainly attributed to the improved SR of premature and non-premature born CDH patients.
This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.